Adalimumab added to Methotrexate and intra-articular glucocorticoid increases remission rates at one year in early, DMARD-naïve patients with rheumatoid arthritis - An investigator-initiated randomized, controlled, double-blinded study. - Ansatte

Adalimumab added to Methotrexate and intra-articular glucocorticoid increases remission rates at one year in early, DMARD-naïve patients with rheumatoid arthritis - An investigator-initiated randomized, controlled, double-blinded study.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt

Kim Hørslev-Petersen
Hetland, Merete Lund
Peter Junker
Jan Pødenphanth
Torkell Ellingsen
Palle Ahlqvist
Hanne M. Lindegaard
Asta Linauskas
Annette Schlemmer
Mette Y. Dam
Ib Hansen
Hans Chr. Horn
Anette Jørgensen
Sophine Boysen Krintel
Johnny Raun
Christian G. Ammizbøll
Johansen, Julia Sidenius
Østergaard, Mikkel
Kristian Stengaard-Pedersen

Adalimumab added to Methotrexate and intra-articular glucocorticoid increases remission rates at one year in early, DMARD-naïve patients with rheumatoid arthritis - An investigator-initiated randomized, controlled, double-blinded study.

Originalsprog	Engelsk
Tidsskrift	Arthritis & Rheumatism
Vol/bind	63
Udgave nummer	10 (suppl.)
Sider (fra-til)	S147
Antal sider	1
ISSN	0004-3591
Status	Udgivet - 2011

ID: 40159956

Institut for Klinisk Medicin

Adalimumab added to Methotrexate and intra-articular glucocorticoid increases remission rates at one year in early, DMARD-naïve patients with rheumatoid arthritis - An investigator-initiated randomized, controlled, double-blinded study.